1-8 of 8
Pieter Sonneveld
Close
Sort by
Journal Articles

Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX

Clinical Trials & Observations
Andrew Spencer, Philippe Moreau, Maria-Victoria Mateos, Hartmut Goldschmidt, Kenshi Suzuki, Mark-David Levin, Pieter Sonneveld, Robert Z. Orlowski, Sung-Soo Yoon, Saad Z. Usmani, Katja Weisel, Donna Reece, Tahamtan Ahmadi, Huiling Pei, Wendy Garvin Mayo, Xue Gai, Jodi Carey, J. Blake Bartlett, Robin Carson, Meletios A. Dimopoulos
Journal: Blood Advances
Blood Adv (2024) 8 (2): 388–398.
https://doi.org/10.1182/bloodadvances.2023010579
Published: 2024
Includes: Supplemental data
Journal Articles

Efficacy and safety of daratumumab combined with all- trans retinoic acid in relapsed/refractory multiple myeloma

Clinical Trials & Observations
Kristine A. Frerichs, Monique C. Minnema, Mark-David Levin, Annemiek Broijl, Gerard M. J. Bos, Marie José Kersten, Tuna Mutis, Christie P. M. Verkleij, Inger S. Nijhof, Patricia W. C. Maas-Bosman, Saskia K. Klein, Sonja Zweegman, Pieter Sonneveld, Niels W. C. J. van de Donk
Journal: Blood Advances
Blood Adv (2021) 5 (23): 5128–5139.
https://doi.org/10.1182/bloodadvances.2021005220
Published: 2021
Includes: Supplemental data
Journal Articles

Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma

Christie P. M. Verkleij, Marloes E. C. Broekmans, Mark van Duin, Kristine A. Frerichs, Rowan Kuiper, A. Vera de Jonge, Martin Kaiser, Gareth Morgan, Amy Axel, Rengasamy Boominathan, Jocelyn Sendecki, Amy Wong, Raluca I. Verona, Pieter Sonneveld, Sonja Zweegman, Homer C. Adams, III, Tuna Mutis, Niels W. C. J. van de Donk
Journal: Blood Advances
Blood Adv (2021) 5 (8): 2196–2215.
https://doi.org/10.1182/bloodadvances.2020003805
Published: 2021
Includes: Supplemental data
Journal Articles

Prognostic and predictive performance of R-ISS with SKY92 in older patients with multiple myeloma: the HOVON-87/NMSG-18 trial

Clinical Trials & Observations
Rowan Kuiper, Sonja Zweegman, Mark van Duin, Martin H. van Vliet, Erik H. van Beers, Belinda Dumee, Michael Vermeulen, Jasper Koenders, Bronno van der Holt, Heleen Visser-Wisselaar, Markus Hansson, Annette W. G. van der Velden, H. Berna Beverloo, Marian Stevens-Kroef, Mark-David Levin, Annemiek Broijl, Anders Waage, Pieter Sonneveld
Journal: Blood Advances
Blood Adv (2020) 4 (24): 6298–6309.
https://doi.org/10.1182/bloodadvances.2020002838
Published: 2020
Includes: Supplemental data
Journal Articles

Search for multiple myeloma risk factors using Mendelian randomization

Molly Went, Alex J. Cornish, Philip J. Law, Ben Kinnersley, Mark van Duin, Niels Weinhold, Asta Försti, Markus Hansson, Pieter Sonneveld, Hartmut Goldschmidt, Gareth J. Morgan, Kari Hemminki, Björn Nilsson, Martin Kaiser, Richard S. Houlston
Journal: Blood Advances
Blood Adv (2020) 4 (10): 2172–2179.
https://doi.org/10.1182/bloodadvances.2020001502
Published: 2020
Includes: Supplemental data
Journal Articles

Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting

Anne Slomp, Laura M. Moesbergen, Jia-nan Gong, Marta Cuenca, Peter A. von dem Borne, Pieter Sonneveld, David C. S. Huang, Monique C. Minnema, Victor Peperzak
Journal: Blood Advances
Blood Adv (2019) 3 (24): 4202–4214.
https://doi.org/10.1182/bloodadvances.2019000702
Published: 2019
Includes: Supplemental data
Journal Articles

A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis

Clinical Trials & Observations
Julie Støve Bødker, Rasmus Froberg Brøndum, Alexander Schmitz, Anna Amanda Schönherz, Ditte Starberg Jespersen, Mads Sønderkær, Charles Vesteghem, Hanne Due, Caroline Holm Nørgaard, Martin Perez-Andres, Mehmet Kemal Samur, Faith Davies, Brian Walker, Charlotte Pawlyn, Martin Kaiser, David Johnson, Uta Bertsch, Annemiek Broyl, Mark van Duin, Rajen Shah, Preben Johansen, Martin Agge Nørgaard, Richard J. Samworth, Pieter Sonneveld, Hartmut Goldschmidt, Gareth J. Morgan, Alberto Orfao, Nikhil Munshi, Hans Erik Johnsen, Tarec El-Galaly, Karen Dybkær, Martin Bøgsted
Journal: Blood Advances
Blood Adv (2018) 2 (18): 2400–2411.
https://doi.org/10.1182/bloodadvances.2018018564
Published: 2018
Includes: Supplemental data
Journal Articles

Should minimal residual disease negativity not be the end point of myeloma therapy?

Clinical Trials & Observations
Pieter Sonneveld
Journal: Blood Advances
Blood Adv (2017) 1 (8): 522–525.
https://doi.org/10.1182/bloodadvances.2017000109
Published: 2017